MS
IOVA icon

Maven Securities’s Iovance Biotherapeutics IOVA Stock Holding History

Maven Securities’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-60,046
Closed -$1.66M – 1156
2021
Q2 		$1.66M Buy
60,046
+2,946
+5% +$76.6K 0.07% 281
2021
Q1 		$1.79M Buy
+57,100
New +$2.37M 0.08% 247
2020
Q4 		– Sell
-240,000
Closed -$7.88M – 699
2020
Q3 		$7.88M Buy
+240,000
New +$7.36M 0.65% 27

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Maven Securities's IOVA Position: Q3 2021 in Review

Maven Securities sold out of Iovance Biotherapeutics (IOVA) in Q3 2021, closing a stake of 60,046 shares — an estimated $1.66M sold.

Maven Securities first reported a position in IOVA in Q3 2020 and held it in 3 quarters. The position peaked at $7.88M in Q3 2020. 243 funds tracked by Wall St. Rank hold IOVA as of Q3 2021.

  • Maven Securities reported no remaining Iovance Biotherapeutics position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 60,046 Iovance Biotherapeutics shares in Q3 2021, an estimated $1.66M.
  • Maven Securities first reported a position in Iovance Biotherapeutics in Q3 2020 and held it in 3 quarters.
  • Maven Securities's Iovance Biotherapeutics position peaked at $7.88M in Q3 2020.
  • 243 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.